Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- 10 September 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (10), 1338-1350
- https://doi.org/10.1016/s1470-2045(18)30495-9
Abstract
No abstract availableKeywords
Funding Information
- Chinese National Natural Science Foundation Project (81572659, 81502355)
- Science and Technology Program of Guangdong (2016A020215084)
- Pearl River Nova Program of Guangzhou (201610010048)
This publication has 36 references indexed in Scilit:
- A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive CancerClinical Cancer Research, 2014
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated MalignanciesClinical Cancer Research, 2013
- Delayed-type Hypersensitivity (DTH) Immune Response Related With EBV-DNA in Nasopharyngeal Carcinoma Treated With Autologous Dendritic Cell Vaccination After RadiotherapyJournal of Immunotherapy, 2013
- Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma PatientsCancer Research, 2013
- Salvage gemcitabine–vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapyOral Oncology, 2012
- A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinomaOral Oncology, 2012
- A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaAnnals of Oncology, 2011
- Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinomaAnnals of Oncology, 2010
- Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinomaHead & Neck, 2005
- Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinomaCancer, 2005